Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in the multisystem inflammatory syndrome in children (MIS-C). The clinical presentation of MIS-C includes fever, severe illness, and the involvement of two or more organ systems, in combination with laboratory evidence of inflammation and laboratory or epidemiologic evidence of SARS-CoV-2 infection. Some features of MIS-C resemble Kawasaki Disease, toxic shock syndrome, and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome. The relationship of MIS-C to SARS-CoV-2 infection suggests that the pathogenesis involves post-infectious immune dysregulation. Patients with MIS-C should ideally be managed in a pediatric intensive care environment since rapid clinical deterioration may occur. Specific immunomodulatory therapy depends on the clinical presentation. The relationship between the immune response to SARS-CoV-2 vaccines in development and MIS-C requires further study.
【저자키워드】 COVID-19, SARS-CoV-2, Kawasaki disease, Toxic shock syndrome, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, multisystem inflammatory syndrome in children (MIS-C), 【초록키워드】 Inflammation, coronavirus, immune response, Pathogenesis, intensive care, SARS-COV-2 infection, pediatric, children, Infection, SARS-CoV-2 vaccine, MIS-C, Laboratory, Shock, Fever, immunomodulatory therapy, Evidence, Combination, Inflammatory, immune dysregulation, organ systems, acute respiratory syndrome, Activation, syndrome, Specific, rapid clinical deterioration, feature, include, occur, 【제목키워드】 review, MIS-C, clinical, presentation,